Comment on "Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes"

J Am Acad Dermatol. 2023 May;88(5):e269. doi: 10.1016/j.jaad.2019.02.066. Epub 2019 Mar 11.

Authors

Claudio Marasca¹, Anna Masarà¹, Maria Carmela Annunziata², Davide Fattore¹, Gabriella Fabbrocini¹

Affiliations

¹ Department of Clinical Medicine and Surgery Section of Dermatology, University of Naples Federico II, Naples, Italy.
² Department of Clinical Medicine and Surgery Section of Dermatology, University of Naples Federico II, Naples, Italy. Electronic address: [email protected].

PMID: 30872151
DOI: 10.1016/j.jaad.2019.02.066

No abstract available

Publication types

Observational Study
Letter
Comment

MeSH terms

Anti-Bacterial Agents / therapeutic use
Clindamycin* / adverse effects
Hidradenitis Suppurativa* / drug therapy
Humans
Prevalence
Rifampin / therapeutic use

Substances

Clindamycin
Rifampin
Anti-Bacterial Agents